Associated Papers
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
White C et al.
Bmc Cancer, 2024
Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review.
Cura Y et al.
Cancers, 2023
Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC et al.
European Journal of Cancer (oxford, England : 1990), 2023
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White C et al.
Clinical Pharmacology and Therapeutics, 2022
Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature.
White C et al.
Pharmacogenomics and Personalized Medicine, 2021
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D et al.
Cancer Treatment Reviews, 2016
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A et al.
British Journal of Cancer, 2013
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation.
Giorgio E et al.
Cancer Chemotherapy and Pharmacology, 2011
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J et al.
Clinical Colorectal Cancer, 2010
[Genetic polymorphisms related to fluoropyrimidine sensitivity and toxicity].
Terashima M
Gan to Kagaku Ryoho. Cancer & Chemotherapy, 2008
Select a paper to view details